A novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR

IF 4.6 2区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL
Junping Zhang, Dylan A. Frabutt, Matthew Chrzanowski, Ning Li, Lohra M. Miller, Jiahe Tian, Patrick L. Mulcrone, Anh K. Lam, Benjamin E. Draper, Martin F. Jarrold, Roland W. Herzog, Weidong Xiao
{"title":"A novel class of self-complementary AAV vectors with multiple advantages based on cceAAV lacking mutant ITR","authors":"Junping Zhang, Dylan A. Frabutt, Matthew Chrzanowski, Ning Li, Lohra M. Miller, Jiahe Tian, Patrick L. Mulcrone, Anh K. Lam, Benjamin E. Draper, Martin F. Jarrold, Roland W. Herzog, Weidong Xiao","doi":"10.1016/j.omtm.2024.101206","DOIUrl":null,"url":null,"abstract":"<p>Self-complementary AAV vectors (scAAV) employ a mutant inverted terminal repeat (mITR) for efficient packaging of complementary stranded DNA, enabling rapid transgene expression. Yet, inefficient resolution at the mITR leads to the packaging of monomeric or subgenomic AAV genomes. These non-canonical particles reduce transgene expression and may affect the safety of gene transfer. To address these issues, we have developed a novel class of scAAV vectors termed covalently closed-end double-stranded AAV (cceAAV) that eliminate the mITR resolution step during production. Instead of employing a mutant ITR, we utilized a 56-bp recognition sequence of protelomerase (TelN) to covalently join the top and bottom strands, allowing the vector to be generated with just a single ITR. To produce cceAAV vectors, the vector plasmid is initially digested with TelN, purified, and then subjected to a standard triple-plasmid transfection protocol followed by traditional AAV vector purification procedures. Such cceAAV vectors demonstrate yields comparable to scAAV vectors. Notably, we observed enhanced transgene expression as compared to traditional scAAV vector. Treatment of mice with hemophilia B with cceAAV-FIX resulted in significantly enhanced long-term FIX expression. The cceAAV vectors hold several advantages over scAAV vectors, potentially leading to development of improved human gene therapy drugs.</p>","PeriodicalId":54333,"journal":{"name":"Molecular Therapy-Methods & Clinical Development","volume":null,"pages":null},"PeriodicalIF":4.6000,"publicationDate":"2024-02-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Molecular Therapy-Methods & Clinical Development","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.omtm.2024.101206","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Self-complementary AAV vectors (scAAV) employ a mutant inverted terminal repeat (mITR) for efficient packaging of complementary stranded DNA, enabling rapid transgene expression. Yet, inefficient resolution at the mITR leads to the packaging of monomeric or subgenomic AAV genomes. These non-canonical particles reduce transgene expression and may affect the safety of gene transfer. To address these issues, we have developed a novel class of scAAV vectors termed covalently closed-end double-stranded AAV (cceAAV) that eliminate the mITR resolution step during production. Instead of employing a mutant ITR, we utilized a 56-bp recognition sequence of protelomerase (TelN) to covalently join the top and bottom strands, allowing the vector to be generated with just a single ITR. To produce cceAAV vectors, the vector plasmid is initially digested with TelN, purified, and then subjected to a standard triple-plasmid transfection protocol followed by traditional AAV vector purification procedures. Such cceAAV vectors demonstrate yields comparable to scAAV vectors. Notably, we observed enhanced transgene expression as compared to traditional scAAV vector. Treatment of mice with hemophilia B with cceAAV-FIX resulted in significantly enhanced long-term FIX expression. The cceAAV vectors hold several advantages over scAAV vectors, potentially leading to development of improved human gene therapy drugs.

Abstract Image

基于缺乏突变 ITR 的 cceAAV 的具有多重优势的新型自补体 AAV 向量
自补体 AAV 载体(scAAV)采用突变倒置末端重复序列(mITR)对互补链 DNA 进行高效包装,从而实现快速转基因表达。然而,由于 mITR 的分辨率不高,导致了单体或亚基因组 AAV 基因组的包装。这些非经典颗粒会降低转基因表达,并可能影响基因转移的安全性。为了解决这些问题,我们开发了一类新型 scAAV 载体,称为共价封闭端双链 AAV(cceAAV),它在生产过程中省去了 mITR 解析步骤。我们没有使用突变的 ITR,而是利用了 56-bp 的原粒体酶(TelN)识别序列来共价连接上下链,从而只用一个 ITR 就能生成载体。要生产 cceAAV 载体,首先要用 TelN 对载体质粒进行消化、纯化,然后采用标准的三重质粒转染方案,再经过传统的 AAV 载体纯化程序。这种 cceAAV 载体的产量与 scAAV 载体相当。值得注意的是,与传统的 scAAV 载体相比,我们观察到了更强的转基因表达。用 cceAAV-FIX 治疗 B 型血友病小鼠可显著提高 FIX 的长期表达。与scAAV载体相比,ceAAV载体具有多种优势,有可能开发出更好的人类基因治疗药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Molecular Therapy-Methods & Clinical Development
Molecular Therapy-Methods & Clinical Development Biochemistry, Genetics and Molecular Biology-Molecular Biology
CiteScore
9.90
自引率
4.30%
发文量
163
审稿时长
12 weeks
期刊介绍: The aim of Molecular Therapy—Methods & Clinical Development is to build upon the success of Molecular Therapy in publishing important peer-reviewed methods and procedures, as well as translational advances in the broad array of fields under the molecular therapy umbrella. Topics of particular interest within the journal''s scope include: Gene vector engineering and production, Methods for targeted genome editing and engineering, Methods and technology development for cell reprogramming and directed differentiation of pluripotent cells, Methods for gene and cell vector delivery, Development of biomaterials and nanoparticles for applications in gene and cell therapy and regenerative medicine, Analysis of gene and cell vector biodistribution and tracking, Pharmacology/toxicology studies of new and next-generation vectors, Methods for cell isolation, engineering, culture, expansion, and transplantation, Cell processing, storage, and banking for therapeutic application, Preclinical and QC/QA assay development, Translational and clinical scale-up and Good Manufacturing procedures and process development, Clinical protocol development, Computational and bioinformatic methods for analysis, modeling, or visualization of biological data, Negotiating the regulatory approval process and obtaining such approval for clinical trials.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信